We are live on ! Find out more
CRXT

Clarus Therapeutics Holdings, Inc. Common Stock
CRXT

Delisted

CRXT was delisted on the 30th of August, 2022.

Back to rankings

13 hedge funds and large institutions have $3.73M invested in Clarus Therapeutics Holdings, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

8% more funds holding

Funds holding: 12 → 13 (+1)

64% less capital invested

Capital invested by funds: $10.5M → $3.73M (-$6.73M)

Holders
13
Holders Change
+1
Holders Change %
+8.33%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
3
Reduced
1
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BCM
Bridgeway Capital Management
Texas
+$114K
2
Millennium Management
Millennium Management
New York
+$49.8K
3
Renaissance Technologies
Renaissance Technologies
New York
+$44.1K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$43.1K
5
UBS Group
UBS Group
Switzerland
+$26.6K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$4.69M
2
PIA
Powell Investment Advisors
Florida
-$156K
3
SSA
Schonfeld Strategic Advisors
New York
-$51K
4
Tudor Investment Corp
Tudor Investment Corp
Connecticut
-$44K
5
Citadel Advisors
Citadel Advisors
Florida
-$31K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCL
1
Bracebridge Capital LLC
Massachusetts
$2.98M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$260K +$10K +7,900 +5%
BCM
3
Bridgeway Capital Management
Texas
$134K +$114K +90,000 New
UBS Group
4
UBS Group
Switzerland
$99K +$26.6K +20,906 +46%
Millennium Management
5
Millennium Management
New York
$58K +$49.8K +39,228 New
Renaissance Technologies
6
Renaissance Technologies
New York
$52K +$44.1K +34,700 New
Geode Capital Management
7
Geode Capital Management
Massachusetts
$50K +$43.1K +33,915 New
Verition Fund Management
8
Verition Fund Management
Connecticut
$45K – – –
VF
9
Virtu Financial
New York
$30K +$25.9K +20,353 New
Citigroup
10
Citigroup
New York
$11K +$9.4K +7,400 New
TRCT
11
Tower Research Capital (TRC)
New York
$6K -$11.4K -8,987 -70%
Royal Bank of Canada
12
Royal Bank of Canada
Ontario, Canada
$1K +$635 +500 New
AC
13
Armistice Capital
New York
– -$4.69M -1,929,876 Closed
PIA
14
Powell Investment Advisors
Florida
– -$156K -64,000 Closed
SSA
15
Schonfeld Strategic Advisors
New York
– -$51K -20,800 Closed
Tudor Investment Corp
16
Tudor Investment Corp
Connecticut
– -$44K -18,148 Closed
Citadel Advisors
17
Citadel Advisors
Florida
– -$31K -12,597 Closed
Wells Fargo
18
Wells Fargo
California
– +$19 +15 +60%

CRXT Hedge Fund Activity: Q1 2022 in Review

13 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) for Q1 2022, worth a combined $3.73M — down 64% from $10.5M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new CRXT positions and 6 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $114K. The largest seller was Armistice Capital, exiting entirely with an estimated $4.69M sold.

  • 13 institutional investors held Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) as of Q1 2022, up from 12 in Q4 2021.
  • Funds reported $3.73M of Clarus Therapeutics Holdings, Inc. Common Stock stock for Q1 2022, down 64% quarter-over-quarter.
  • 7 funds opened new Clarus Therapeutics Holdings, Inc. Common Stock positions in Q1 2022 and 6 closed out, a net change of +1 holder.
  • The largest Clarus Therapeutics Holdings, Inc. Common Stock buyer in Q1 2022 was Bridgeway Capital Management, an estimated $114K added.
  • The largest Clarus Therapeutics Holdings, Inc. Common Stock seller in Q1 2022 was Armistice Capital, an estimated $4.69M sold.

Based on aggregated 13F filings for Q1 2022.